OGI
Organigram Global Inc. Common Shares
Pharmaceutical Preparations
Best Pharmaceutical Stocks 2026 →
OGI Stock Analysis: Buy, Sell, or Hold?
$0.83
-0.02 (-2.50%)
▼
5d:
-10.48%
30d:
-7.91%
90d:
-32.33%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (57%)
Quality Score
44/100
Position
OVERSOLD
30-Day Fair Range
$0.91 – $0.99
Position: OVERSOLD
Forward P/E & Valuation
35.6x
CHEAP
vs 55.5x historical avg
Wall Street Target
$8.80
+930.8% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$0.82 / $0.98
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR STABILIZATION: OGI is down 10.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Get Alerted When OGI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: OGI is currently trading at $0.83, which is considered oversold relative to its 30-day fair value range of $0.91 to $0.99. From a valuation perspective, the stock is trading at a discount (Forward PE: 35.6) compared to its historical average (55.5). Remarkably, the market is currently pricing in an annual earnings decline of 13.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, OGI is in a strong uptrend. The price is currently testing key support at $0.82. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: OGI scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.80 (+930.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OGI is in a strong uptrend. The price is currently testing key support at $0.82. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: OGI scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.80 (+930.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.91 -
$0.99
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Trading Range & Key Levels
30-Day Trading Range
$0.91 -
$0.99
Current vs Trading Range
OVERSOLD
Support Level
$0.82
Resistance Level
$0.98
Current Trend
Strong Uptrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 930.8% below Wall St target ($8.80)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
35.57
Wall Street Target
$8.80
(+930.8%)
Revenue Growth (YoY)
49.4%
Profit Margin
28.0%
Valuation Discount vs History
-13.8% cheaper
PE vs Historical
35.6 vs 55.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-13.8%
(market-implied from PE analysis)
1-Year Target
$0.77
(-10%)
2-Year Target
$0.69
(-19%)
3-Year Target
$0.62
(-27%)
3-Yr Target (if PE normalizes)
(PE: 36→56)
$0.97
(+14%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 35.6, Growth: -94.5%)
$0.62
(+-27%)
Base:
(SPY PE: 19.9, Growth: -94.5%)
$0.35
(-59%)
Bear:
(PE: 16.9, Growth: -94.5%)
$0.30
(-65%)
📈
Valuation based on Current Earnings
Trailing PE: 2.03 | Current EPS (TTM): $0.42
Bull Case
$0.47
(-45%)
Analyst growth -50.0%, PE expands to 2.2
Base Case
$0.43
(-50%)
Market implied -50.0%, PE stable at 2.0
Bear Case
$0.58
(-32%)
Severe decline -20.0%, PE contracts to 1.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 35.6 to 55.5
Stabilization Target:
$1.33
(+56.0%)
PE Expansion Potential:
+56.0%
Share OGI Analysis
Share this live OGI analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (OGI)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 4, 2026
Daily AI digest
AI Retail Discussion Summary:
Curaleaf reaffirms superior bid for Aurora Cannabis, expresses concerns over Organigram deal details and Aurora's board actions
Key Retail Themes:
M&A activity in the cannabis industry
Curaleaf's ongoing bid for Aurora Cannabis
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 3:27 PM ET
Data refreshes hourly during market hours. Next update: 4:27 PM
Data refreshes hourly during market hours. Next update: 4:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OGI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$208 | 23 SELL |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$58 | 41 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
15 analysts |
$49 | 36 SELL |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$63 | 51 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive OGI Research Pages
